{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:49:01Z","timestamp":1785466141372,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02174-5","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:02:21Z","timestamp":1692288141000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors"],"prefix":"10.1007","volume":"47","author":[{"given":"S.","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pedersini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Carrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciafardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Balzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-2141","authenticated-orcid":false,"given":"A. G.","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-701X","authenticated-orcid":false,"given":"G.","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"issue":"3","key":"2174_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2174_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Gl\u00fcer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of aromatase inhibitor-associated bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"issue":"10001","key":"2174_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"EBCTCG","year":"2015","unstructured":"EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"issue":"10","key":"2174_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","volume":"123","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123(10):877\u2013884. https:\/\/doi.org\/10.1016\/j.amjmed.2010.02.028","journal-title":"Am J Med"},{"issue":"7","key":"2174_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s40618-023-02056-w","volume":"46","author":"L Cianferotti","year":"2023","unstructured":"Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania AG, Messina C, Napoli N, Mazziotti G (2023) Bone quality in endocrine diseases: determinants and clinical relevance. J Endocrinol Invest 46(7):1283\u20131304. https:\/\/doi.org\/10.1007\/s40618-023-02056-w","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2174_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69(1):73\u201382. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2174_CR7","doi-asserted-by":"publisher","first-page":"101654","DOI":"10.1016\/j.bonr.2023.101654","volume":"18","author":"R Pedersini","year":"2023","unstructured":"Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri FM, di Mauro P, Maffezzoni F, Monteverdi S, Vena W, Laini L, Amoroso V, Simoncini EL, Farina D, Mazziotti G, Berruti A (2023) Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: a single center cross-sectional study. Bone Rep 18:101654. https:\/\/doi.org\/10.1016\/j.bonr.2023.101654","journal-title":"Bone Rep"},{"issue":"4","key":"2174_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jocd.2019.07.006","volume":"22","author":"K Krohn","year":"2019","unstructured":"Krohn K, Schwartz EN, Chung YS, Lewiecki EM (2019) Dual-energy X-ray absorptiometry monitoring with trabecular bone score: 2019 ISCD Official Position. J Clin Densitom 22(4):501\u2013505. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.006","journal-title":"J Clin Densitom"},{"issue":"3","key":"2174_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jocd.2011.05.005","volume":"14","author":"D Hans","year":"2011","unstructured":"Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14(3):302\u2013312. https:\/\/doi.org\/10.1016\/j.jocd.2011.05.005","journal-title":"J Clin Densitom"},{"issue":"5","key":"2174_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.20945\/2359-3997000000559","volume":"66","author":"T Palomo","year":"2022","unstructured":"Palomo T, Muszkat P, Weiler FG, Dreyer P, Brand\u00e3o CMA, Silva BC (2022) Update on trabecular bone score. Arch Endocrinol Metab 66(5):694\u2013706. https:\/\/doi.org\/10.20945\/2359-3997000000559","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2174_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-016-3899-6","volume":"28","author":"AR Hong","year":"2017","unstructured":"Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28(4):1413\u20131422. https:\/\/doi.org\/10.1007\/s00198-016-3899-6","journal-title":"Osteoporos Int"},{"issue":"11","key":"2174_CR12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40618-019-01063-0","volume":"42","author":"A Catalano","year":"2019","unstructured":"Catalano A, Gaudio A, Agostino RM, Morabito N, Bellone F, Lasco A (2019) Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors. J Endocrinol Invest 42(11):1337\u20131343. https:\/\/doi.org\/10.1007\/s40618-019-01063-0","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2174_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40618-014-0125-2","volume":"37","author":"M Pedrazzoni","year":"2014","unstructured":"Pedrazzoni M, Casola A, Verzicco I, Abbate B, Vescovini R, Sansoni P (2014) Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J Endocrinol Invest 37(9):871\u2013874. https:\/\/doi.org\/10.1007\/s40618-014-0125-2","journal-title":"J Endocrinol Invest"},{"issue":"31","key":"2174_CR14","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/jco.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37(31):2916\u20132946. https:\/\/doi.org\/10.1200\/jco.19.01696","journal-title":"J Clin Oncol"},{"issue":"9596","key":"2174_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, Initiative S (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"1","key":"2174_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68(1):1\u201339. https:\/\/doi.org\/10.4081\/reumatismo.2016.870","journal-title":"Reumatismo"},{"issue":"29","key":"2174_CR17","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.20.00434","volume":"38","author":"A Dalla Volta","year":"2020","unstructured":"Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, Maroldi R, Berruti A (2020) Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol 38(29):3363\u20133366. https:\/\/doi.org\/10.1200\/JCO.20.00434","journal-title":"J Clin Oncol"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"100421","DOI":"10.1016\/j.jbo.2022.100421","volume":"33","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti G, Vena W, Pedersini R, Piccini S, Morenghi E, Cosentini D, Zucali P, Torrisi R, Sporeni S, Simoncini EL, Maroldi R, Balzarini L, Lania AG, Berruti A (2022) Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice. J Bone Oncol 33:100421. https:\/\/doi.org\/10.1016\/j.jbo.2022.100421","journal-title":"J Bone Oncol"},{"issue":"3","key":"2174_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00198-013-2567-3","volume":"25","author":"EM Clark","year":"2014","unstructured":"Clark EM, Carter L, Gould VC, Morrison L, Tobias JH (2014) Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening. Osteoporos Int 25(3):953\u2013964. https:\/\/doi.org\/10.1007\/s00198-013-2567-3","journal-title":"Osteoporos Int"},{"issue":"1","key":"2174_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","volume":"42","author":"JF Griffith","year":"2012","unstructured":"Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42(1):39\u201351. https:\/\/doi.org\/10.1007\/s12020-012-9691-2","journal-title":"Endocrine"},{"issue":"1","key":"2174_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11657-019-0577-2","volume":"14","author":"K Engelke","year":"2019","unstructured":"Engelke K, Stampa B, Steiger P, Fuerst T, Genant HK (2019) Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry. Arch Osteoporos 14(1):18. https:\/\/doi.org\/10.1007\/s11657-019-0577-2","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2174_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bone.2005.04.003","volume":"37","author":"GG Crans","year":"2005","unstructured":"Crans GG, Genant HK, Krege JH (2005) Prognostic utility of a semiquantitative spinal deformity index. Bone 37(2):175\u2013179. https:\/\/doi.org\/10.1016\/j.bone.2005.04.003","journal-title":"Bone"},{"issue":"4","key":"2174_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International society for clinical densitometry position development conference on bone densitometry. J Clin Densitom 16(4):455\u2013466. https:\/\/doi.org\/10.1016\/j.jocd.2013.08.004","journal-title":"J Clin Densitom"},{"issue":"5","key":"2174_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Od\u00e9n A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJM, Fujita Y, Gl\u00fcer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren \u00d6, Lorentzon M, Mellstr\u00f6m D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31(5):940\u2013948. https:\/\/doi.org\/10.1002\/jbmr.2734","journal-title":"J Bone Miner Res"},{"key":"2174_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02082-8","author":"G Adami","year":"2023","unstructured":"Adami G, Biffi A, Porcu G, Ronco R, Alvaro R, Bogini R, Caputi AP, Cianferotti L, Frediani B, Gatti D, Gonnelli S, Iolascon G, Lenzi A, Leone S, Migliaccio S, Nicoletti T, Paoletta M, Pennini A, Piccirilli E, Tarantino U, Brandi ML, Corrao G, Rossini M, Michieli R (2023) A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS. J Endocrinol Investig. https:\/\/doi.org\/10.1007\/s40618-023-02082-8","journal-title":"J Endocrinol Investig"},{"key":"2174_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194148","author":"F Bertoldo","year":"2022","unstructured":"Bertoldo F, Cianferotti L, Di Monaco M, Falchetti A, Fassio A, Gatti D, Gennari L, Giannini S, Girasole G, Gonnelli S, Malavolta N, Minisola S, Pedrazzoni M, Rendina D, Rossini M, Chiodini I (2022) Definition, assessment, and management of vitamin D inadequacy\u202f: suggestions, recommendations, and warnings from the Italian society for osteoporosis, mineral metabolism and bone diseases (SIOMMMS). Nutrients. https:\/\/doi.org\/10.3390\/nu14194148","journal-title":"Nutrients"},{"key":"2174_CR27","doi-asserted-by":"publisher","first-page":"h3868","DOI":"10.1136\/bmj.h3868","volume":"351","author":"M Pavlou","year":"2015","unstructured":"Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, Omar RZ (2015) How to develop a more accurate risk prediction model when there are few events. BMJ 351:h3868. https:\/\/doi.org\/10.1136\/bmj.h3868","journal-title":"BMJ"},{"issue":"1","key":"2174_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13643-023-02181-w","volume":"12","author":"M Gates","year":"2023","unstructured":"Gates M, Pillay J, Nuspl M, Wingert A, Vandermeer B, Hartling L (2023) Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools. Syst Rev 12(1):51. https:\/\/doi.org\/10.1186\/s13643-023-02181-w","journal-title":"Syst Rev"},{"issue":"5","key":"2174_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jbmr.4250","volume":"36","author":"H Lu","year":"2021","unstructured":"Lu H, Lei X, Zhao H, Elting L, Siricilla M, Ursani MA, Giordano SH, Suarez-Almazor M (2021) Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer. J Bone Miner Res 36(5):861\u2013871. https:\/\/doi.org\/10.1002\/jbmr.4250","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2174_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","volume":"111","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti G, Pedersini R, Vena W, Cosentini D, Carrone F, Pigni S, Simoncini EL, Torrisi R, Zambelli A, Farina D, Balzarini L, Lania AG, Berruti A (2022) Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral Fractures in women with breast cancer undergoing treatment with aromatase inhibitors. Calcif Tissue Int 111(5):466\u2013474. https:\/\/doi.org\/10.1007\/s00223-022-01011-w","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2174_CR31","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-017-4140-y","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C (2017) Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporosis Int 28(10):2967\u20132973. https:\/\/doi.org\/10.1007\/s00198-017-4140-y","journal-title":"Osteoporosis Int"},{"issue":"7","key":"2174_CR32","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00198-014-2703-8","volume":"25","author":"C Senn","year":"2014","unstructured":"Senn C, G\u00fcnther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25(7):1945\u20131951. https:\/\/doi.org\/10.1007\/s00198-014-2703-8","journal-title":"Osteoporos Int"},{"key":"2174_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4764","author":"F Cosman","year":"2023","unstructured":"Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B (2023) Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVExtend. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.4764","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2174_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.11005\/jbm.2022.29.4.279","volume":"29","author":"C Jeong","year":"2022","unstructured":"Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH (2022) Effect of romosozumab on trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. J Bone Metab 29(4):279. https:\/\/doi.org\/10.11005\/jbm.2022.29.4.279","journal-title":"J Bone Metab"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2016.08.008","volume":"92","author":"MP-MM Rodr\u00edguez-Sanz","year":"2016","unstructured":"Rodr\u00edguez-Sanz MP-MM, Servitja S, Garcia-Giralt N, Martos T, Tusquets I, Mart\u00ednez-Garc\u00eda M, Rodriguez-M D-P, Albanell J, Nogu\u00e9s X (2016) TBS and BMD at the end of AI-therapy: a prospective study of the B-ABLE cohort. Bone 92:1\u20138. https:\/\/doi.org\/10.1016\/j.bone.2016.08.008","journal-title":"Bone"},{"key":"2174_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2016.03.010","volume":"90","author":"C Prasad","year":"2016","unstructured":"Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S (2016) Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial. Bone 90:123\u2013126. https:\/\/doi.org\/10.1016\/j.bone.2016.03.010","journal-title":"Bone"},{"key":"2174_CR37","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.bonr.2021.101105","volume":"15","author":"LBF Iconaru","year":"2021","unstructured":"Iconaru LBF, Charles A, Mugisha A, Benoit F, Surquin M, Karmali R, Body JJ, Bergmann P (2021) Which treatment to prevent an imminent fracture? Bone Rep 15:101105. https:\/\/doi.org\/10.1016\/j.bonr.2021.101105","journal-title":"Bone Rep"},{"key":"2174_CR38","doi-asserted-by":"publisher","first-page":"116187","DOI":"10.1016\/j.bone.2021.116187","volume":"154","author":"YJ Hu","year":"2022","unstructured":"Hu YJ, Chines A, Shi Y, Seeman E, Guo XE (2022) The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: a post-hoc HR-pQCT study. Bone 154:116187. https:\/\/doi.org\/10.1016\/j.bone.2021.116187","journal-title":"Bone"},{"issue":"7","key":"2174_CR39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jbmr.4006","volume":"35","author":"DW Dempster","year":"2020","unstructured":"Dempster DW, Chines A, Bostrom MP, Nieves JW, Zhou H, Chen L, Pannacciulli N, Wagman RB, Cosman F (2020) Modeling-based bone formation in the human femoral neck in subjects treated with denosumab. J Bone Miner Res 35(7):1282\u20131288. https:\/\/doi.org\/10.1002\/jbmr.4006","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2174_CR40","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C De Laet","year":"2005","unstructured":"De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16(11):1330\u20131338. https:\/\/doi.org\/10.1007\/s00198-005-1863-y","journal-title":"Osteoporos Int"},{"issue":"9","key":"2174_CR41","doi-asserted-by":"publisher","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","volume":"2","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, Formenti AM, Dalla Volta A, Simoncini EL, Giustina A, Maroldi R, Berruti A (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open 2(9):e1911080. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11080","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2174_CR42","doi-asserted-by":"publisher","first-page":"e10440","DOI":"10.1002\/jbm4.10440","volume":"5","author":"S Monteverdi","year":"2021","unstructured":"Monteverdi S, Pedersini R, Gallo F, Maffezzoni F, Dalla Volta A, Di Mauro P, Turla A, Vassalli L, Ardine M, Formenti AM, Simoncini EL, Giustina A, Maroldi R, Amoroso V, Berruti A (2021) The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy. JBMR Plus 5(2):e10440. https:\/\/doi.org\/10.1002\/jbm4.10440","journal-title":"JBMR Plus"},{"issue":"5","key":"2174_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00223-012-9643-0","volume":"91","author":"D Diacinti","year":"2012","unstructured":"Diacinti D, Del Fiacco R, Pisani D, Todde F, Cattaruzza MS, Diacinti D, Arima S, Romagnoli E, Pepe J, Cipriani C, Minisola S (2012) Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography. Calcif Tissue Int 91(5):335\u2013342. https:\/\/doi.org\/10.1007\/s00223-012-9643-0","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2174_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","volume":"41","author":"CB Confavreux","year":"2007","unstructured":"Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41(3):346\u2013352. https:\/\/doi.org\/10.1016\/j.bone.2007.06.004","journal-title":"Bone"},{"issue":"5","key":"2174_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2018.05.003","volume":"32","author":"P Szulc","year":"2018","unstructured":"Szulc P (2018) Bone turnover: biology and assessment tools. Best Pract Res Clin Endocrinol Metab 32(5):725\u2013738. https:\/\/doi.org\/10.1016\/j.beem.2018.05.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2174_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40618-022-01901-8","volume":"46","author":"W Vena","year":"2023","unstructured":"Vena W, Carrone F, Delbarba A, Akpojiyovbi O, Pezzaioli LC, Facondo P, Cappelli C, Leonardi L, Balzarini L, Farina D, Pizzocaro A, Lania AG, Mazziotti G, Ferlin A (2023) Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndrome. J Endocrinol Invest 46(2):297\u2013304. https:\/\/doi.org\/10.1007\/s40618-022-01901-8","journal-title":"J Endocrinol Invest"},{"key":"2174_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02150-z","author":"A Dalla Volta","year":"2023","unstructured":"Dalla Volta A, Palumbo C, Zamboni S, Mazziotti G, Triggiani L, Zamparini M, Maffezzoni F, Rinaudo L, Bergamini M, Di Meo N, Caramella I, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Berruti A (2023) Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02150-z","journal-title":"J Endocrinol Invest"},{"key":"2174_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12891-016-0886-1","volume":"17","author":"S Amnuaywattakorn","year":"2016","unstructured":"Amnuaywattakorn S, Sritara C, Utamakul C, Chamroonrat W, Kositwattanarerk A, Thamnirat K, Ongphiphadhanakul B (2016) Simulated increased soft tissue thickness artefactually decreases trabecular bone score: a phantom study. BMC Musculoskelet Disord 17:17. https:\/\/doi.org\/10.1186\/s12891-016-0886-1","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"2174_CR49","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00198-022-06549-x","volume":"33","author":"D Hans","year":"2022","unstructured":"Hans D, Shevroja E, McDermott M, Huang S, Kim M, McClung M (2022) Updated trabecular bone score accounting for the soft tissue thickness (TBS(TT)) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. Osteoporos Int 33(12):2517\u20132525. https:\/\/doi.org\/10.1007\/s00198-022-06549-x","journal-title":"Osteoporos Int"}],"updated-by":[{"DOI":"10.1007\/s40618-023-02208-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02174-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T02:20:12Z","timestamp":1707704412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02174-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40618-023-02208-y","asserted-by":"object"}]},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40618-023-02208-y","URL":"https:\/\/doi.org\/10.1007\/s40618-023-02208-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following competing financial interests: Dr Pedersini received consultancy fees from Roche, Novartis, Eli Lilly, Daiichi Sankyo, Gilead, Eisai, Accord, outside the submitted work; Dr. Torrisi received\u00a0research grants\u00a0from Pfizer, consultancy fees from MSD and\u00a0lecture fees from Pfizer, Eli Lilly, EISAI and Genomic Health outside the submitted work; Dr. Vena received grants from IBSA Pharmaceutical outside the submitted work; Dr. Zambelli received consultancy fees from Roche, Novartis, Pfizer, Eli Lilly & Co., AstraZeneca, Genomic Health outside the submitted work; Dr. Bossi received research grants from Novo-Nordisk, Eli Lilly, Bayer, Sanofi Italia and advisory board and consultancy fees from MSD, Alfasigma, Boehringer Ingelheim, Astra Zeneca, Mundipharma Italia, Pfizer outside the submitted work; Dr. Lania received grants from Pfizer and consultancy fees from Ipsen, outside the submitted work; Dr. Berruti reports receiving grants and personal fees from Janssen Cilag, grants and personal fees from Astellas, and personal fees from Bayer outside the submitted work; Dr. Mazziotti received consultancy fees from Novartis, Ipsen, Eli Lilly and lecture fees from Amgen and Abiogen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of IRCCS Humanitas Research Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Research involving human participants and\/or animals"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and all participants gave their written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No Informed Consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}